Soliris

Soliris^® (eculizumab) is a first-in-class terminal complement inhibitor discovered, developed and commercialized by Alexion. Soliris works by inhibiting terminal complement, a normal part of the immune system that, when activated inappropriately, plays a role in serious diseases like PNH and aHUS.

Soliris is also approved for the treatment of patients with atypical hemolytic uremic syndrome (aHUS), a catastrophic, ultra-rare genetic disease in which a deficiency in one or more of the complement regulatory genes causes chronic, uncontrolled complement activation that can result in sudden and progressive damage to vital organs, leading to stroke, heart attack, kidney failure and premature death. 

Soliris is the first and only therapy approved for the treatment of patients with aHUS, and is specifically indicated in this population to inhibit complement-mediated thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body.